Tusamitamab ravtansine is a Monoclonal Antibody Conjugated owned by Sanofi, and is involved in 9 clinical trials, which are ongoing.

Tusamitamab ravtansine specifically targets the carcinoembryonic (CEA or CEACAM5) antigen expressed in many cancers, including colorectal cancer. Carcinoembryonic antigens (CEA) are highly glycosylated proteins attached to the exterior of the tumor cell membrane, where they function as cell adhesion molecules and play a role in tumorigenesis. The drug candidate may act by inducing a cytotoxic effect on cells which express CEACAM5.

The revenue for Tusamitamab ravtansine is expected to reach a total of $850m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tusamitamab ravtansine NPV Report.

Tusamitamab ravtansine was originated by ImmunoGen and is currently owned by Sanofi.

Tusamitamab ravtansine Overview

Tusamitamab ravtansine is under development for the treatment of solid tumors including metastatic non- squamous non-small cell lung cancer, colorectal cancer, non-squamous non-small cell lung cancer (NSCLC), small cell lung cancer, gastric adenocarcinoma, squamous cell carcinoma of the cervix, pancreas adenocarcinoma, bladder transitional cell carcinoma, esophago-gastric junction adenocarcinoma, cholangiocarcinoma, epithelial ovarian cancer, endometrial adenocarcinoma, metastatic breast cancer (mBC), triple-negative breast cancer (TNBC) and metastatic pancreatic adenocarcinoma (mPAC). The drug candidate is administered through intravenous route as a solution concentrate. The drug candidate targets carcinoembryonic antigen related cell adhesion molecule 5 (CEACAM5 or CD66e). It is a new molecular entity (NME).

Sanofi Overview

Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

The company reported revenues of (Euro) EUR39,175 million for the fiscal year ended December 2021 (FY2021), an increase of 4.8% over FY2020. In FY2021, the company’s operating margin was 20.7%, compared to an operating margin of 37.8% in FY2020. In FY2021, the company recorded a net margin of 15.9%, compared to a net margin of 32.9% in FY2020. The company reported revenues of EUR13,138 million for the third quarter ended September 2022, a decrease of 36.8% over the previous quarter.

Quick View – Tusamitamab ravtansine

Report Segments
  • Innovator
Drug Name
  • Tusamitamab ravtansine
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.